Darbepoetin alfa for the treatment of anemia in myelodysplastic syndromes: a post-marketing surveillance study in Japan
Yasuyoshi Morita, Yukie Tsuji, Tomoharu Yasukawa, Kinuko Mitani · 2026
Read Darbepoetin alfa for the treatment of anemia in myelodysplastic syndromes: a post-marketing surveillance study in Japan by Yasuyoshi Morita, Yukie Tsuji, Tomoharu Yasukawa, Kinuko Mitani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13638701.txt.
Description
Yasuyoshi Morita, Yukie Tsuji, Tomoharu Yasukawa, and Kinuko Mitani report a post market watch study in Japan of darbepoetin alfa for anemia in myelodysplastic syndromes, bone marrow ills that cut blood counts. The watch ran for years after the drug's launch. The study came out in twenty twenty-six.
Near two thousand patients, most of them old, were tracked for five years from care start. Risk groups were mostly low or mid low. Side effects were told in three fourths of patients, with lung infection most common and shift to acute leukemia next. Blood counts rose past a key line within a year. Over half cut their transfusion need by half or more.
Catalog record
| CREATOR | Yasuyoshi Morita, Yukie Tsuji, Tomoharu Yasukawa, Kinuko Mitani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |